Trial Profile
Non-Interventional Study on Edoxaban Treatment in Routine Clinical Practice for Patients With Non Valvular Atrial Fibrillation
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 20 Feb 2024
Price :
$35
*
At a glance
- Drugs Edoxaban (Primary)
- Indications Cardiovascular disorders; Embolism; Embolism and thrombosis; Stroke
- Focus Adverse reactions
- Acronyms ETNA-AF-EU; ETNA-AF-Europe
- Sponsors Daiichi Sankyo Company; Daiichi Sankyo Inc
- 28 Aug 2023 Results (n=13164) assessing long-term effectiveness and safety of edoxaban in patients with atrial fibrillation presented at the ESC Congress 2023 - Annual Congress of the European Society of Cardiology
- 28 Aug 2023 Results of sub analysis assessing of perceived versus objective frailty on outcome events in patients with AF treated with edoxaban during the 4-year follow-up of the ETNA-AF-Europe registry presented at the ESC Congress 2023 - Annual Congress of the European Society of Cardiology
- 13 Oct 2022 Results of sub analysis assessing the prevalence of frailty (Perceived vs. objective frailty) in patients with atrial fibrillation and impact on anticoagulant dosing published in the Europace